A Hybrid Deep Architecture for Face Recognition in Real-Life Scenario

Amartya Sanyal,U. Bhattacharya,S. K. Parui

DOI: https://doi.org/10.1007/978-3-319-68124-5_11

2016-12-19

Abstract:

What problem does this paper attempt to address?

Clinical and biological heterogeneity in triple-negative breast cancer and HER2-low.

Xi'e Hu,Ping Yang,Songhao Chen,Gang Wei,Lijuan Yuan,Zhenyu Yang,Lin Yang,Shujia Peng,Yanming Dong,Xianli He,Guoqiang Bao

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.e12565

IF: 45.3

2023-06-01

Journal of Clinical Oncology

Abstract:e12565 Background: HER2-low could be found in some patients with triple-negative breast cancer (TNBC). However, its potential impacts on clinical features and tumor biological characteristics in TNBC remain unclear. Methods: We enrolled 251 consecutive TNBC patients retrospectively, including 157 HER2-low (HER2 low ) and 94 HER2-negtive (HER2 neg ) patients to investigate the clinical and prognostic features. Then, we performed single-cell RNA sequencing (scRNA-seq) with another seven TNBC samples (HER2 neg vs. HER2 low , 4 vs. 3) prospectively to further explore the differences of tumor biological properties between the two TNBC phenotypes. The underlying molecular distinctions were also explored and then verified in the additional TNBC samples. Results: Compared with HER2 neg TNBC, HER2 low TNBC patients exhibited malignant clinical features with larger tumor size ( P = 0.04), more lymph nodes involvement ( P = 0.02), higher histological grade of lesions ( P < 0.001), higher Ki67 status ( P < 0.01), and a worse prognosis ( P < 0.001; HR [CI 95%] = 3.44 [2.10-5.62]). Cox proportional hazards analysis showed that neoadjuvant systemic therapy, lymph nodes involvement and Ki67 levels were prognostic factors in HER2 low TNBC but not in HER2 neg TNBC patients. scRNA-seq revealed that HER2 low TNBC which showed more metabolically active and aggressive hallmarks, while HER2 neg TNBC exhibited signatures more involved in immune activities with higher expressions of immunoglobulin-related genes ( IGHG1, IGHG4, IGKC, IGLC2); this was further confirmed by immunofluorescence in clinical TNBC samples. Furthermore, HER2 low and HER2 neg TNBC exhibited distinct tumor evolutionary characteristics. Moreover, HER2 neg TNBC revealed a potentially more active immune microenvironment than HER2 low TNBC, as evidenced by positively active regulation of macrophage polarization, abundant CD8 + effector T cells, enriched diversity of T-cell receptors and higher levels of immunotherapy-targeted markers, which contributed to achieve immunotherapeutic response. Conclusions: This study suggests that HER2 low TNBC patients harbor more malignant clinical behavior and aggressive tumor biological properties than the HER2 neg phenotype. The heterogeneity of HER2 may be a non-negligible factor in the clinical management of TNBC patients. Our data provides new insights into the development of a more refined classification and tailored therapeutic strategies for TNBC patients.

oncology
HER2-Low Status Was Associated With Better Breast Cancer-Specific Survival in Early-Stage Triple-Negative Breast Cancer

Youzhao Ma,Dechuang Jiao,Jingyang Zhang,Minhao Lv,Xiuchun Chen,Zhenzhen Liu

DOI: https://doi.org/10.1093/oncolo/oyad275

2024-03-04

Abstract:Background: Based on the association between the hormone receptor and the status of human epidermal growth factor receptor 2 (HER2)-low, we investigated the clinicopathological and prognostic characteristics of the HER2-low status in early-stage triple-negative breast cancer (TNBC). Methods: We collected the data of patients with TNBC who received treatment at our hospital and compared the pathological complete response (pCR) rate, overall survival (OS), and breast cancer-specific survival (BCSS) between the HER2-0 and HER2-low subtypes. Results: A total of 1445 patients were included in the study, of which 698 patients (48.3%) showed HER2-low status. A similar pCR rate was observed between HER2-0 and HER2-low patients (34.9% vs. 37.4%; P = .549). T staging, N staging, and HER2 status were associated with BCSS, whereas T staging and N staging were associated with OS. Patients with the HER2-low status showed better BCSS than those with the HER2-0 status (96.6% vs. 93.7%; log-rank P = .027). In patients with non-pCR, the BCSS of the HER2-low subgroup was better than that of the HER2-0 subgroup (log-rank P = .047); however, no similar result was observed in patients with pCR. In patients with stage III, the BCSS and OS of the HER2-low subgroup were better than those of the HER2-0 subgroup (BCSS, log-rank P = .010; OS, log-rank P = .047). No similar results were observed in patients with stages I and II. Conclusion: The HER2-low expression was associated with better BCSS in TNBC, especially in the high-risk groups, suggesting that HER2-low breast cancer is a potential independent biological subtype.
Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer

Yongcheng Chen,Yanfei Ma,Yanghong Li,Yanrong Yu,Bimin Lu,Liangyan Liao,Fujun Li,Zipeng Wen,Wenjun Jiang,Pengwei Guo,Dalang Fang,Guanming Lu

DOI: https://doi.org/10.21037/gs-22-747

2023-02-09

Gland Surgery

Abstract:Background: Human epidermal growth factor receptor 2 (HER2) is a landmark protein in determining the targeted treatment of breast cancer (BC). However, the latest research shows that different intensity of HER2 protein expression levels in BC leads to different clinical characteristics, treatment, and prognosis, especially in HER2 low expression patients. Therefore, this study intends to analyze and compare the clinicopathologic features and prognosis of BC patients with low and zero HER2 expression from The Cancer Genome Atlas (TCGA) database and the data collected by our center.Methods: First, the BC dataset was downloaded from TCGA database, including 345 eligible and with complete clinical information BC patients, to compare the difference between HER2 low expression groups and HER2 zero expression groups and their correlation with estrogen receptor (ER) and progesterone receptor (PR) expression. Then, the clinicopathological data and follow-up of 405 patients with HER2 low expression and HER2 zero expression diagnosed with BC admitted to the Affiliated Hospital of Youjiang Medical University for Nationalities (YJMU) from January 2017 to December 2021 were collected to verify the consistency of the results of the two data sets.Results: Both the clinical samples and the TCGA data showed that the ER and PR rates were higher in the HER2 low expression group compared with the HER2 zero expression group. There were no significant differences in tumor size, lymph node metastasis, distant metastasis, and disease-free survival (DFS). In addition, the data analysis of 405 clinical samples also showed that the HER2 low expression group had a lower 3-year recurrence or metastasis rate compared with the HER2 zero expression group.Conclusions: Compared with HER2 zero expression, HER2 low patients express more ER and PR, and have less short-term recurrence and metastasis, but there is no obvious difference in DFS between the two groups.

surgery
Clinicopathologic Characteristics of Triple-Negative Breast Cancer

Ning Lü,Wei Han,Caiping Chen,Wanxin Wu,Xin Wen,Yanping Zhang,Zheng-ying Tang,Ling Yuan,Qin Yu,Wei Guo

DOI: https://doi.org/10.3760/cma.j.issn.1007-631x.2009.06.019

2009-01-01

Abstract:Objective To study the clinicopathologic characteristics of triple-negative breast cancer (TNBC) and its value in the prediction of prognosis. Method In this study,500 cases of female breast cancers were examined immunohistochcmically for the TNBC. The clinicopathologic characteristics of the 243 TNBC cases were inspected. Results TNBC accounted for 17.6% (88/500) of the 500 breast cancers. The histological types of the TNBC included mainly infihrative ductal carcinoma, metaplastic carcinoma and medullar carcinoma. Among those, histological grade Ⅲ accounted for 72.7% (64/88) of all the TNBC and was more common than that in hormone receptor positive breast cancers (HR+ group ) and Her-2 overexpression breast cancers (Her-2 group)(P=0.000). The positive rates of CK5/6 and EGFR in the TNBC were 30.7% (27/88) and 34.1% (30/88), respectively. The positive rates of ERCC1 and KIT in the TNBC were 28.4% (25/88) and 34.1% (30/88), respectively, Both of which were higher than those in the HR + group and Her-2 group, respectively (P=0.032 and P=0.026). 3-year survival rate of the TNBC was 71.5% and it was lower than that of HR group (P=0.021) and not significantly different from that of Her-2 group (P=0.474). Conclusions TNBC is the breast cancer with high aggressive pathologic futures and poor prognosis. EGFR and ERCC1 expression were positive in a portion of TNBC cases. Key words: Breast neoplasms; Receptors, estrogen; Receptor, progestogen; Genes, erbB-2
[Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].

X J Zhu,H Zhang,S Zhang,D Li,X Li,L Xu,T Li

DOI: https://doi.org/10.19723/j.issn.1671-167x.2023.02.007

2023-01-01

Abstract:OBJECTIVE:There is an increasing interest in human epidermal growth factor receptor 2 (HER2) low expression breast cancer with the result of novel anti-HER2 antibody-drug conjugates for breast cancer. HER2 low expression breast cancer is expected to become a new type of breast cancer. This study analyzed and compared the clinicopathological features and survival data of breast cancer with HER2 low expression group [immunohistochemistry (IHC) 1+ or IHC 2+, and fluorescence in situ hybridization (FISH) negative] and HER2 zero expression group (IHC 0), in order to explore the difference in clinical biology of HER2 low expression breast cancers. METHODS:Among 1 250 female patients with primary non-metastatic breast cancer admitted to the Breast Disease Center of Peking University First Hospital from January 2014 to December 2017, 969 cases were HER2 negative (IHC 0, 1+, 2+, and FISH was not amplified). The clinicopathologic features and prognosis of the patients with HER2 low expression (IHC 1+ or 2+, and unamplified by FISH) and HER2 zero expression (IHC 0) were analyzed. Disease free survival (DFS) and overall survival (OS) were evaluated, survival rates were calculated by Kaplan-Meier curve, and survival differences were compared by Log-rank test. Cox regression analysis of univariate and multivariate prognostic factors. Bilateral test was used, and P < 0.05 was considered statistically significant. RESULTS:In the 969 patients with HER2 negative breast cancer, 606 had HER2 low expression (62.54%) and 363 had HER2 zero expression (37.46%). Compared with breast cancer with HER2 zero expression, those with HER2 low expression had higher N stage (P=0.001) and TNM stage (P=0.044), the proportion of non-specific histological types was higher (82.7% vs. 79.1%, P=0.009), the histological grade was higher (P=0.048), and the positive rate of hormone receptor was higher (83.2% vs. 75.2%, P=0.003). The percentage of Ki-67 value index >30% was lower (30.4% vs. 36.6%, P=0.044). There was no significant difference in DFS and OS between the two groups (P>0.05). In the 969 cases, 777 were hormone receptor positive and 192 were hormone receptor negative (triple negative cancer). Among the 777 cases with hormone receptor positive, 504 (64.9%) were HER2 low expression, and 273 (35.1%) were HER2 zero expression. Compared with breast cancer with HER2 zero expression group, the HER2 low expression group had a younger age (P=0.016), a higher proportion of premenopausal patients (P=0.029), more lymph node involvement (P=0.002), and a higher total TNM stage (P=0.031), and less frequent histological types of lobular and mucinous carcinoma (3.6% vs. 7.3%, 4.8% vs. 10.6%, P=0.001). There was no difference in DFS and OS between HER2 low expression and zero expression (P>0.05). Among 192 patients with hormone receptor negative, there were 102 cases (53.1%) with HER2 low expression and 90 cases (46.9%) with HER2 zero expression. Compared with the HER2 zero expression groups, HER2 low expression group was older (P=0.001), the proportion of premenopausal patients was low (P=0.029), the histological grade was lower (P < 0.001), the Ki-67 value index was lower (P < 0.001), and androgen receptor positive rate was higher (58.8% vs. 34.4%, P < 0.001). DFS was better than HER2 zero expression group (P=0.038), but there was no difference in OS between the two groups (P>0.05). CONCLUSION:HER2 low expression breast cancer accounts for about half of all breast cancers, and the incidence is much higher than that of HER2 positive breast cancer. Its clinicopathologic features are heterogeneous, and the status of hormone receptor expression has an impact on the clinical biology of this group.
A Study on Pertinence of Pathologic and Biology Features in HER-2, ER and PR Negative Breast Cancer

ZHANG Yi,WANG Yan,CAO Yong-xian,CAO Ming-zhi,LI Yu-jun,LIANG Jun

DOI: https://doi.org/10.3760/cma.j.issn.1008-1372.2010.11.008

2010-01-01

Abstract:Objective To analyze the pathologic and biology features and prognosis of HER-2, ER and PR negative breast cancer (TNBC). Methods Clinic pathologic data of 329 breast cancer patients was retrospectively analyzed. The expression of HER-2, ER, PR and P53 was determined by immunohisto-chemistry. The patients were divided into three groups, including TN group [HER-2 (-), ER (-), PR (-)], HER-2 group [HER-2 (+), ER (-), PR (-)] and HR group [ER (+), PR (-) or (+), HER-2 (-) or (+)]. The pathology and biology features and P53 masculine expression of the three groups were compared. The 5-year overall survival and disease free survival were analyzed by Kaplan-Meier method. Results Of the 329 patients, 20.97% (69/329) was TN group, 34.04% (112/329) was HER-2 group, and 44.98% (148/329) was HR group. The percentage of with lymph node metastasis in TN group 55.07% (38/69) was higher than that in HER-2 group 42.86% (48/112) and HR group 43.24% (64/148) (χ^2= 12.57, P＜0.05). The rates of P53 positive, operation recurrence and metastasis in TN group were 44.93%, 27.54% and 20.29%, which were higher than that in HER-2 group (20.54%, 16.07%, 16.96%) and HR group (18.24%, 12.84%, 10.81%) (χ^2=12.23, 8.36, P＜0.05). The ratio of tumor ≥5cm, Ⅲ stages, Ⅲ grade and soakage canula cancer among three groups had statistical difference (χ^2= 7.25, 8.79, 9.23, 8.48, P＜0.05). The 5-year overall survival in three groups were 75.36%, 82.14%, 85.14% and disease free survival were 68.12%, 78.57%, 82.43% (χ^2=8.52, P＜0.05). Conclusion The pathology and biology traits of TNBC were high rate of P53 (+) and recurrence and lymph node metastasis. The most important factor for poor prognosis of TNBC was the low rate of disease free survival for 5 years.
Triple-negative Breast Cancer Types Exhibit a Distinct Poor Clinical Characteristic in Lymph Node-Negative Chinese Patients

Zhe-Bin Liu,Guang-Yu Liu,Wen-Tao Yang,Gen-Hong Di,Jin-Song Lu,Kun-Wei Shen,Zhen-Zhou Shen,Zhi-Min Shao,Jiong Wu

DOI: https://doi.org/10.3892/or_00000100

1994-01-01

Oncology Reports

Abstract:Comparative studies on the clinical features and outcomes of triple-negative subgroups to human epidermal growth factor receptor-2 (HER-2) overexpression, and luminal A and B subgroups in lymph node-negative breast cancer patients, are important to correctly evaluate clinical prognosis. A total of 1132 Chinese breast cancer patients were enrolled in a retrospective analysis. We characterized and identified prognostic information in the triple-negative subgroup [estrogen receptor (ER)-, progesterone receptor (PR)- and HER-2-negative] and compared that to HER-2 overexpression, and the luminal A and B subgroups. By using immunohistochemical staining, the triple-negative subgroup showed 17% (193/1132) in the whole group. However, HER-2 overexpression, and the luminal A and B subgroups were 11.2, 47.9 and 23.9%, respectively. Tumors in the triple-negative subgroup showed a higher histological grade (P=0.025) and lower invasive ductal carcinoma (P=0.007), compared to the three subgroups. More patients in the luminal A subgroup had received adjuvant chemotherapy (P=0.007). The difference of disease-free survival rates among the four subgroups was significant (P=0.0001). The P-value for overall survival was 0.0598. No significant difference among the four subgroups in lymph node-positive and non-chemotherapy breast cancers was found. From our data the poor clinical outcomes were independent of age, histological grade, tumor size, lymph nodal status, chemotherapy and clinical stages. Our data suggest that the triple-negative subgroup exhibits a distinct poor clinical outcome, especially in lymph node-negative Chinese breast cancer patients.
Genomic Alterations of Tumors in HER2-Low Breast Cancers

Yi-Fang Tsai,Chi-Cheng Huang,Chih-Yi Hsu,Chin-Jung Feng,Yen-Shu Lin,Ta-Chung Chao,Jiun-I Lai,Pei-Ju Lien,Chun-Yu Liu,Jen-Hwey Chiu,Ling-Ming Tseng

DOI: https://doi.org/10.3390/ijms25021318

IF: 5.6

2024-01-22

International Journal of Molecular Sciences

Abstract:The aim of this study was to elucidate molecular profiling in HER2-low tumors based on a promising dataset. A total of 615 consecutive HER2-negative breast cancer samples were assayed. The genomic mutations in the two groups with different HER2 expression levels (HER2-0 vs. HER2-low) were compared. The mutation types obtained via next-generation targeted sequencing were correlated with the clinicopathological features of the patients with HER2-0 and HER2-low breast cancer. The results showed that there was a significantly higher percentage of receptor-positive (ER/PR) tumors and more low-level Ki-67 tumors, but a lower incidence of stage I/II tumors in the HER2-low group compared to the HER2-0 group. There was a significantly higher frequency of 17.62% (65/369) for PIK3CA_SNA in the HER2-low group than in the HER2-0 group, which had a frequency of only 9.35% (23/246) (p =0.006). When the called gene alterations in the triple-negative breast cancer (TNBC) group were compared with those in the luminal-like breast cancer group, there was a significantly high frequency of 28.17% (140/497) for ERBB2_SNA in a luminal-like group than in the TNBC group(16.95% (20/118)).We conclude that the early detection of PIK3CA mutations is likely to be important and might help therapeutic decision making in patients with HER2-low tumors.

biochemistry & molecular biology,chemistry, multidisciplinary
Clinicopathologic and Genomic Features in Triple-Negative Breast Cancer Between Special and No-Special Morphologic Pattern

Ying-Zi Li,Bo Chen,Xiao-Yi Lin,Guo-Chun Zhang,Jian-Guo Lai,Cheukfai Li,Jia-Li Lin,Li-Ping Guo,Wei-Kai Xiao,Hsiaopei Mok,Chong-Yang Ren,Ling-Zhu Wen,Fang-Rong Cao,Xin Lin,Xiao-Fang Qi,Yang Liu,Ning Liao

DOI: https://doi.org/10.3389/fonc.2022.830124

IF: 4.7

2022-03-25

Frontiers in Oncology

Abstract:Background Triple-negative breast cancer (TNBC) is refractory and heterogeneous, comprising various entities with divergent phenotype, biology, and clinical presentation. As an aggressive subtype, Chinese TNBC patients with special morphologic patterns (STs) were restricted to its incidence of 10-15% in total TNBC population. Methods We recruited 89 patients with TNBC at Guangdong Provincial People’s Hospital (GDPH) from October 2014 to May 2021, comprising 72 cases of invasive ductal carcinoma of no-special type (NSTs) and 17 cases of STs. The clinical data of these patients was collected and statistically analyzed. Formalin-fixed, paraffin-embedded (FFPE) tumor tissues and matched blood samples were collected for targeted next-generation sequencing (NGS) with cancer-related, 520- or 33-gene assay. Immunohistochemical analysis of FFPE tissue sections was performed using anti-programmed cell death-ligand 1(PD-L1) and anti-androgen receptor antibodies. Results Cases with NSTs presented with higher histologic grade and Ki-67 index rate than ST patients (NSTs to STs: grade I/II/III 1.4%, 16.7%,81.9% vs 0%, 29.4%, 58.8%; p<0.05; Ki-67 ≥30%: 83.3% vs. 58.8%, p<0.05), while androgen receptor (AR) and PD-L1 positive (combined positive score≥10) rates were lower than of STs cases (AR: 11.1% vs. 47.1%; PD-L1: 9.6% vs. 33.3%, p<0.05). The most commonly altered genes were TP53 (88.7%), PIK3CA (26.8%), MYC (18.3%) in NSTs, and TP53 (68.8%), PIK3CA (50%), JAK3 (18.8%), KMT2C (18.8%) in STs respectively. Compared with NSTs, PIK3CA and TP53 mutation frequency showed difference in STs (47.1% vs 19.4%, p=0.039; 64.7% vs 87.5%, p=0.035). Conclusions In TNBC patients with STs, decrease in histologic grade and ki-67 index, as well as increase in PD-L1 and AR expression were observed when compared to those with NSTs, suggesting that TNBC patients with STs may better benefit from immune checkpoint inhibitors and/or AR inhibitors. Additionally, lower TP53 and higher PIK3CA mutation rates were also found in STs patients, providing genetic evidence for deciphering at least partly potential mechanism of action.

oncology
Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients

Zhaoxu Chen,Huiqing Jia,Huina Zhang,Lifang Chen,Peng Zhao,Jing Zhao,Guangming Fu,Xiaoming Xing,Yujun Li,Chengqin Wang

DOI: https://doi.org/10.1007/s10549-023-07079-8

2023-08-28

Breast Cancer Research and Treatment

Abstract:Abstract Objective This study aims to analyze whether there are any differences in clinicopathological features and prognosis between HER2 ultra-low, HER2-null, and HER2-low expression in Chinese breast cancer (BC) patients. Methods The clinicopathological data of 1363 HER2-negative BC patients were retrospectively collected (from January 2018 to December 2019). HER2 status was further classified into HER2-null, HER2 ultra-low, and HER2-low. HER2-null expression is defined as infiltrating cancer cells completely free of staining. HER2 ultra-low expression is defined as ≤10% of infiltrating cancer cells showing incomplete and faint/weak membrane staining. HER2-low expression is defined as HER2 immunohistochemistry (IHC) 1+ or 2+ with negative in situ hybridization (ISH) assay. Results Of 1363 patients, there were 86 (6.3%) HER2-null patients, 395 (29.0%) HER2 ultra-low patients, and 882 (64.7%) HER2-low patients. HER2 ultra-low patients were different from HER2-low patients in terms of N stage, hormone receptor (HR) status, Ki-67 expression, and type of surgery. There were also significant differences in histologic type and postoperative endocrine therapy between HER2 ultra-low and HER2-null patients. HR+ (81.0%) tumors was more common than HR− (19.0%) in HER2 ultra-low patients. In addition, there was a significant difference in HR status between HER2 ultra-low and HER2-low patients ( P = 0.001). The survival analysis showed that HER2 status had no effect on disease-free survival (DFS) in HER2-negative patients (all P > 0.05). However, regardless of HER2 status, HR+ patients had better DFS than HR− patients ( P = 0.003). Cox multivariate analysis revealed that age (HR [95% CI] = 0.950 [0.928, 0.972], P < 0.001), HR status (HR [95% CI] = 3.342 [1.658, 6.736], P = 0.001), and postoperative endocrine therapy (HR [95% CI] = 0.048 [0.048, 0.023], P < 0.001) were important influencing factors of DFS in HER2-negative BC patients. Conclusion HER2 ultra-low BC patients demonstrated distinct clinicopathological features from HER2-null and HER2-low tumors; while, HER2 status (null, ultra-low, or low) had no prognostic value in these HER2-negative BC population. Consistent with the published literature, HR status was an independent prognostic factor for DFS in HER2-negative BC patients.

oncology
Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers

William Jacot,Aurélie Maran-Gonzalez,Océane Massol,Charlotte Sorbs,Caroline Mollevi,Séverine Guiu,Florence Boissière-Michot,Jeanne Ramos

DOI: https://doi.org/10.3390/cancers13236059

2021-12-01

Cancers

Abstract:HER2-low breast cancer (i.e., HER 1+ or 2+, without gene amplification) is an emerging subtype for which very few data are available, especially within the triple-negative breast cancer (TNBC) group. Our aim was to evaluate HER2 expression and its prognostic value in a large retrospective series of patients with non-metastatic TNBC (median age: 57.7 years; range: 28.5–98.6). Among the 296 TNBC samples, 83.8% were HER2 0, 13.5% were HER2 1+, and 2.7% were HER2 2+ (HercepTestTM and 2018 ASCO/CAP guidelines for HER2 scoring). CK5/6 and/or EGFR-expressing androgen receptors and FOXA1-expressing tumors were classified as basal-like (63.8%) and molecular apocrine-like (MA, 40.2%), respectively. Compared with HER2 0 tumors, HER2 1+/2+ tumors exhibited a lower histological grade (1/2) (35.4% vs. 18.2%, p = 0.007) and MA profile (57.5% vs. 36.7%, p = 0.008). Moreover, patients with HER2 1+/2+ tumors were older (p = 0.047). After a median follow-up of 9.7 years, HER2 2+ tumors (compared with HER2 0/1+ tumors) were associated with worse relapse-free survival (RFS) (HR = 3.16, 95% CI [1.27; 7.85], p = 0.034) in a univariate analysis. Overall survival (OS) and RFS were not different in the HER2 0 and 1+/2+ groups. HER2 levels were not significantly associated with OS or RFS in a multivariate analysis.

oncology
Molecular characteristics and prognosis of breast cancer patients with different level of HER2 positivity after adjuvant and neoadjuvant chemotherapy

Dilihumaer Tuluhong,Xinfang Li,Hongyu Gao,Yueyun Zhu,Qiurong Li,Shaohua Wang

DOI: https://doi.org/10.1097/cej.0000000000000813

2023-05-20

European Journal of Cancer Prevention

Abstract:Purpose HER2-low breast cancer (BC) has renewed interests of researchers worldwide. Here, we aimed to investigate the clinicopathological characteristics of patients with HER2-low, HER2-0 and HER2 ultra-low BC and make conclusion. Methods We collected cases of patients who were diagnosed as BC at Jingling General hospital. Immunohistochemistry was used to redefine HER2 scores. Kaplan–Meier methods and Cox proportional hazards regression analysis were used to compare survival. Results We found that HER2-low BC was more frequent in hormone receptor (HR)–positive BC patients and was associated with fewer T3-T4, lower breast conserving surgery rate and higher adjuvant chemotherapy rate. HER2-low BC patients had better overall survival (OS) compared to HER2-0 BC in premenopausal and stage II BC. Furthermore, HER2-0 BC patients had lower Ki-67 expression levels compared to HER2-ultra low and HER2-low BC in HR–negative BC. HER2-0 BC patients also had worse OS rate compared to those with HER2-ultra low BC in HR–positive BC. Finally, HER2-0 BC patients showed a higher pathological response rate compared to those with HER2-low BC after neoadjuvant chemotherapy. Conclusions These findings suggest that HER2-low BC has distinct biology and clinical features compared to HER2-0 BC, and more investigation is needed to understand the biology of HER2-ultra low BC.

oncology
Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer

Ruo Qi Li,Lei Yan,Ling Zhang,Hai Xia Ma,Hui Wen Wang,Peng Bu,Yan Feng Xi,Jing Lian

DOI: https://doi.org/10.1038/s41598-024-62991-3

IF: 4.6

2024-05-30

Scientific Reports

Abstract:Triple-negative breast cancer (TNBC) has high heterogeneity, poor prognosis, and limited treatment success. Recently, an immunohistochemistry-based surrogate classification for the "Fudan University Shanghai Cancer Center (FUSCC) subtyping" has been developed and is considered more suitable for clinical application. Seventy-one paraffin-embedded sections of surgically resected TNBC were classified into four molecular subtypes using the IHC-based surrogate classification. Genomic analysis was performed by targeted next-generation sequencing and the specificity of the subtypes was explored by bioinformatics, including survival analysis, multivariate Cox regression, pathway enrichment, Pyclone analysis, mutational signature analysis and PHIAL analysis. AKT1 and BRCA1 mutations were identified as independent prognostic factors in TNBC. TNBC molecular subtypes encompass distinct genomic landscapes that show specific heterogeneities. The luminal androgen receptor (LAR) subtype was associated with mutations in PIK3CA and PI3K pathways, which are potentially sensitive to PI3K pathway inhibitors. The basal-like immune-suppressed (BLIS) subtype was characterized by high genomic instability and the specific possession of signature 19 while patients in the immunomodulatory (IM) subtype belonged to the PD-L1 ≥ 1% subgroup with enrichment in Notch signaling, suggesting a possible benefit of immune checkpoint inhibitors and Notch inhibitors. Moreover, mesenchymal-like (MES) tumors displayed enrichment in the receptor tyrosine kinase (RTK)-RAS pathway and potential sensitivity to RTK pathway inhibitors. The findings suggest potential treatment targets and prognostic factors, indicating the possibility of TNBC stratified therapy in the future.

multidisciplinary sciences
Abstract P1-11-06: Multi-omics Profiling of HER2-low Breast Cancer Reveals Clinically Relevant Subgroups and Therapeutic Pathways

Lie Chen,Cui-Cui Liu,Jing-Yu Ge,Zhi-Ming Shao,Ke-da Yu

DOI: https://doi.org/10.1158/1538-7445.sabcs22-p1-11-06

IF: 11.2

2023-01-01

Cancer Research

Abstract:Abstract The current HER2 testing algorithm can distinguish tumors that are completely negative for HER2 (IHC 0, HER2-zero) from HER2-low tumors [low (IHC 1+) or moderate expression (IHC 2+, ISH-)]. Because HER2-zero cases have often been combined with HER2-low cases, the clinical and biological understanding of HER2-low tumors is limited. To provide complementary information and shed light on the molecular characteristics and therapeutic insights of HER2-low breast cancer, we performed this multi-omics study of hormone receptor (HR)-negative and HER2-low breast cancer, also known as HER2-low triple-negative breast cancer (TNBC), and identified three subgroups: basal-like (BSL), receptor tyrosine kinase relevant (TKR), and mesenchymal stem-like (MSL). These three subgroups had distinct features and potential therapeutic targets and were validated in external datasets. Interestingly, the TKR subgroup (which exists in both HR-positive and HR-negative breast cancer) had activated HER2 and downstream MAPK signaling. In vitro and in vivo patient-derived xenograft experiments revealed that pretreatment with tyrosine kinase inhibitor (Lapatinib or Tucatinib) could inhibit HER2-signaling and induce accumulated expression of nonfunctional HER2 via a feedback loop, resulting in increased sensitivity to sequential HER2-targeting antibody-drug conjugate DS-8201. Our findings identify clinically relevant subgroups and provide potential therapeutic strategies for the previously targetless HER2-low TNBC subtype. GRAPH ABSTRACT Highlights of characteristics of HR-negative and HER2-low breast cancer subgroups Table S1. Highlights of characteristics of HR-negative and HER2-low breast cancer subgroups. Citation Format: Lie Chen, Cui-Cui Liu, Jing-Yu Ge, Zhi-Ming Shao, Ke-da Yu. Multi-omics profiling of HER2-low breast cancer reveals clinically relevant subgroups and therapeutic pathways [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P1-11-06.
Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review

Jin Wang,Dongying Liao,Xuemin Zhang,Changhong Miao,Kuang Chen

DOI: https://doi.org/10.2147/BCTT.S407181

2023-04-22

Breast Cancer: Targets and Therapy

Abstract:Jin Wang, 1– 3, &ast Dongying Liao, 1– 3, &ast Xuemin Zhang, 1– 3 Changhong Miao, 1– 3 Kuang Chen 1– 3 1 Department of Emergency, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, People's Republic of China; 2 National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, People's Republic of China; 3 Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People's Republic of China &astThese authors contributed equally to this work Correspondence: Kuang Chen, Department of Emergency, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Anshanxi Road, Nankai District, Tianjin, 300193, People's Republic of China, Tel +86 18622150281, Email Breast cancer (BC) poses a severe threat to the health of women worldwide. Currently, different therapeutic regimens are used for BC according to the pathological classification of HER2-positive or HER2-negative. Clinical reports of HER2-low expression indicate that the condition is HER2-negative, which was ineligible for HER2-targeted therapy. In contrast to HER2-zero tumors, however, HER2-low BC is a heterogeneous disease with unique genetic characteristics, prognoses, and different therapeutic responses. Clinical efficacy has been demonstrated by numerous potent and innovative anti-HER2 medications, particularly antibody–drug conjugates (ADCs). Certain ADCs, including T-DXd, have demonstrated good efficacy in some trials either used alone or in conjunction with other medications. To enhance outcomes in individuals with HER2-low BC, immunotherapy and other treatments are frequently combined with HER2-targeted therapy. There are also alternative strategies that target both HER2 and HER3 or other antigenic sites. We hope more individuals with HER2-low BC will benefit from more precise treatment regimens in the future. This article provides a review of existing research and clinical trials. Keywords: HER2-low breast cancer, monoclonal antibodies, antibody–drug conjugates, trastuzumab deruxtecan, immunotherapy Breast cancer (BC) has become the most commonly diagnosed tumor in women worldwide. 1 Human epidermal growth factor receptor 2 (HER2)-positive BC accounted for about 15% of all cases and was considered a poor prognostic predictor in the past. However, the survival outcomes of these patients have improved considerably and were similar to HER2-negative with the evolution of anti-HER2 agents. 2–6 In the past, HER2-low BC could not gain clinical benefit from conventional anti-HER2 agents like trastuzumab. 7 However, with the introduction of novel anti-HER2 compounds, BC with low levels of HER2 expression and no detectable Erb-B2 receptor tyrosine kinase 2 (ERBB2) gene amplification might also derive benefit. The efficacy was found when anti-HER2 agents were combined with other therapies such as immunotherapy. According to the updated 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, the HER2 status is assessed to evaluate HER2 protein expression levels by IHC (immunohistochemistry) and HER2 gene status by ISH (in situ hybridization). 8 HER2-low is defined as IHC1+ or IHC2+ without gene amplification, accounting for about 55%. 9,10 The application of the new guidelines leads to an increase in the negativity rate on HER2 testing for the reclassification of Group 2 and Group 4 cases. 11 The refinement of future diagnostics may be needed to assess HER2 status more accurately. Based on the expression of hormone receptors (HR) and the status of HER2, BC is classified into four intrinsic molecular subtypes: luminal A (HR-positive and HER2-negative), luminal B (HR-positive and HER2-positive), HER2 enriched (HR-negative and HER2-positive), and triple-negative BC (TNBC, HR-negative and HER2-negative). 12 The four subtypes of tumors have different prognoses, and TNBC is generally considered to be the worst. 13 The possibility of improving the treatment of HER2-low BC has great clinical significance. Also, different treatment approaches for the four subtypes, respectively. In clinical practice, HER2-low BC was reported as HER2-negative, which was classified as TNBC or luminal-like. However, HER2-low BC is a heterogeneous disease, which showed distinctive molecular features. 9,14 Compared with HER2-zero tumors, HER2-low BC has a higher rate of HR-positive (64–88%), 9,15 a higher disease-free survival (DFS) and overall survival (OS), 16 and a limited immune response. 17 This implies that they may have differences in response to therapy, and different therapeutic strategies are nee -Abstract Truncated-
Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: A single-center retrospective study

Chang-Gen Liu,Yi-Fan Li,Tian-Yi Ma,Meng Lv,Zhi-Dong Lv,Yuan-Yuan Wang,Xiang-Ping Liu,Yan Mao,Hai-Bo Wang

DOI: https://doi.org/10.3389/fonc.2023.1130734

IF: 4.7

2023-03-29

Frontiers in Oncology

Abstract:Background Owing to the emergence of drugs targeting human epidermal growth factor receptor 2 (HER2), remarkable prognostic enhancement has been seen for patients with HER2-positive breast carcinoma. However, anti-HER2 medicines are applicable merely to individuals with HER2-positive tumors, and the benefit for those with low HER2 expression is unclear. The DESTINY-Breast04 phase III and RC48 clinical trial results showed the benefit of antibody-drug couples for low HER2-expressing individuals with breast carcinoma, challenging the traditional dichotomy between HER2-negative and -positive tumors. Hence, the purposes of the present work are to explore the clinicopathological traits and prognostic differences in the HER2-low expression Chinese population with early-stage breast carcinoma. Methods Data from the database of the Breast Center of the Affiliated Hospital of Qingdao University were collected from January 2008 to December 2017. We screened a total of 4,598 patients, of which 2,837 had HER2-0 tumors and 1,761 had HER2-low tumors. Additionally, clinicopathological characteristics, survival, and prognostic information were obtained. Difference comparisons were made between HER2-0 and HER2-low groups regarding the clinical traits and outcomes. Results We enrolled 4598 patients, with the HR-positive subjects suffering from HER2-low breast carcinoma higher in proportion than the HR-negative patients. In contrast to HER2-0 tumors, the HER2-low tumors were linked to an older median age at diagnosis, T1 tumors, N1 stage, a higher Ki-67 index, as well as inferior histological grade. Insignificant inter-group difference was noted regarding overall survival (OS), although the HER2–0 group exhibited better disease-free survival (DFS) than the HER2-low group for the entire (P = 0.003), lymph node-negative (P = 0.009) and HR-positive (P = 0.007) populations. According to the multivariate regression finding, low HER2 expression was an inferior DFS prognostic factor in the HER2-negative population with early-stage breast cancer (HR,1.33;95% CI, 1.06-1.66; P = 0.013). Conclusion The clinical traits of the HER2-low carcinomas differed from those of HER2–0 tumors. Despite the insignificant inter-group difference in OS, the differences in DFS were found for the overall, lymph node-negative and HR-positive subjects, suggesting the possibility of HER2-low as an inferior prognostic factor for disease progression in early-stage breast cancer.

oncology
Evolving Perspectives in Clinical Landscape and Molecular Characteristics of HER2-Low Breast Cancer and Beyond

Juan Jin,Bin Li,Jianing Cao,Ting Li,Jian Zhang,Jun Cao,Leiping Wang,Zhonghua Tao,Xichun Hu

DOI: https://doi.org/10.2139/ssrn.4159640

2022-01-01

SSRN Electronic Journal

Abstract:Background: The novel HER2-directed antibody-drug conjugates prompt the identification of the HER2-low subtype in breast cancer, defined as HER2 immunohistochemical (IHC) 1+, or 2-positive without ERBB2 amplification.Methods: Our retrospective study reviewed clinical and biological data from 579 metastatic breast cancer patients undergoing Next Generation Sequencing (NGS) testing.Results: First, HER2-low tumors were more frequently HR (hormone receptor)-positive and the clinicopathological characteristics of HER2-low patients were associated with HR status. Second, quite a number of HER2-zero (HER2 IHC-0) primary tumors would translate to HER2-low ones in the metastatic sites, even up to 48.4% in HR-positive tumors, highlighting the importance of revaluation of metastatic lesions. Third, the metastatic traits of HER2-low tumors were more like to HER2-positive ones in HR-positive subtype with more brain and lung metastasis and de novo stage IV breast cancer. Fourth, although mutation, copy number variation and mRNA profiles were similar between HER2-low and HER2-zero tumors, different to HER2-positive ones, some differences still were observed between HER2-low and HER2-zero tumors, including rates of BRCA2 germline mutations and PIK3CA and TP53 somatic mutations. Fifth, HER2-low tumors had a longer overall survival (OS) and disease-free survival (DFS) versus HER2-zero tumors, but no difference was observed when paired by HR status. Finally, three molecular subtypes based on genomic alterations in HER2-low breast cancer were identified and Cluster 2 enriched of TP53 mutations was significantly associated worse clinical outcomes, which provided novel insights into heterogeneity in HER2-low breast cancer.Conclusions: Although the clinical and molecular significance of HER2-low status was influenced by HR status, HER2-low tumors indeed had some distinct features in subtype analysis based on HR status. Our results of molecular subtypes in HER2-low tumors encouraged clinicians to concern the heterogeneity in HER2-low breast cancer.
In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China

Yiqun Li,Nilupai Abudureheiyimu,Hongnan Mo,Xiuwen Guan,Shaoyan Lin,Zijing Wang,Yimeng Chen,Shanshan Chen,Qiao Li,Ruigang Cai,Jiayu Wang,Yang Luo,Ying Fan,Peng Yuan,Pin Zhang,Qing Li,Fei Ma,Binghe Xu

DOI: https://doi.org/10.3389/fonc.2021.774577

IF: 4.7

2022-01-17

Frontiers in Oncology

Abstract:Background To characterize the clinical and pathological features and survival of patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer in China. Methods The China National Cancer Center database was used to identify 1,433 metastatic breast cancer patients with HER2-negative disease diagnosed between 2005 and 2015. Clinicopathological features, survival, and prognosis information were extracted. Overall survival (OS) was estimated using the Kaplan–Meier method and compared using the log-rank test. Prognostic factors associated with OS were analyzed using Cox regression model with 95% confidence interval (95% CI). Results There were 618 (43.1%) and 815 (56.9%) HER2-low and HER2-zero tumors out of 1,433 tumors, respectively. The proportion of hormone receptor (HR)-positive tumors was significantly higher in HER2-low tumors than in those with HER2-zero tumors (77.8% vs. 69.2%, p < 0.001). Patients with HER2-low tumors survived significantly longer than those with HER2-zero tumors in the overall population (48.5 months vs. 43.0 months, p = 0.004) and HR-positive subgroup (54.9 months vs. 48.1 months, p = 0.011), but not in the HR-negative subgroup (29.5 months vs. 29.9 months, p = 0.718). Multivariate regression analysis revealed that HER2-low tumors were independently associated with increased OS in HER2-negative population (HR: 0.85, 95% CI: 0.73–0.98, p = 0.026). Conclusion Our findings demonstrate that HER2-low tumors could be identified as a more distinct clinical entity from HER2-zero tumors, especially for the HR-positive subgroup. A more complex molecular landscape of HER2-low breast cancer might exist, and more precise diagnostic algorithms for HER2 testing could be investigated, thus offering new therapeutic targets for breast cancer treatment.

oncology
Multiomics and single-cell sequencings reveal the specific biological characteristics of low Ki-67 triple-negative breast cancer

Boyue Han,Xiangchen Han,Hong Luo,Javaria Nasir,Chao Chen,Zhiming Shao,Hong Ling,Xin Hu

DOI: https://doi.org/10.1002/cai2.146

2024-09-19

Abstract:Background: Triple-negative breast cancer (TNBC) displays high heterogeneity. The majority of TNBC cases are characterized by high Ki-67 expression. TNBC with low Ki-67 expression accounts for only a small fraction of cases and has been relatively less studied. Methods: This study analyzed a large single-center multiomics TNBC data set, combined with a single-cell data set. The clinical, genomic, and metabolic characteristics of patients with low Ki-67 TNBC were analyzed. Results: The clinical and pathological characteristics were analyzed in 2217 TNBC patients. Low Ki-67 TNBC was associated with a higher patient age at diagnosis, a lower proportion of invasive ductal carcinoma, increased alterations in the PI3K-AKT-mTOR pathway, upregulated lipid metabolism pathways, and enhanced infiltration of M2 macrophages. High Ki-67 TNBC exhibited a higher prevalence of TP53 gene mutations, elevated nucleotide metabolism, and increased infiltration of M1 macrophages. Conclusions: We identified specific genomic and metabolic characteristics unique to low Ki-67 TNBC, which have implications for the development of precision therapies and patient stratification strategies.
Abstract HER2-10: HER2-10 Dynamics of HER2-low expression in triple-negative breast cancer

Ana C. Garrido-Castro,Lan D. Ngo,Edward T. Richardson,Allison Frangieh,Ayesha Mohammed-Abreu,Melissa E. Hughes,Jorge Gomez Tejada Zanudo,John Navarro,Paolo Tarantino,Elizabeth A. Mittendorf,Sara Tolaney,Tari King,Eric Winer,Nancy U. Lin,Nikhil Wagle

DOI: https://doi.org/10.1158/1538-7445.sabcs22-her2-10

IF: 11.2

2023-03-04

Cancer Research

Abstract:Background: With the development of novel antibody drug conjugates (ADC), it is increasingly important to understand the changes that occur in cell-surface targets over time from early-stage to metastatic breast cancer. Discordance in HER2 expression per immunohistochemistry (IHC) has been reported between primary and metastatic tumors in patients (pts) with HER2-negative breast cancer defined per ASCO/CAP guidelines, with both gain and loss of expression described. Representation of HR-negative (TNBC) tumors has been limited in these studies, and HER2 status at multiple time points in TNBC has not been described. Here we report changes in HER2 IHC in patients diagnosed with TNBC, using a collection of matched tumor samples over time. Methods: Pts were identified from two sources: 1) an institutional database including all consecutive pts who underwent surgery for stage I-III breast cancer at Dana-Farber/Brigham Cancer Center between 2015-2018, and 2) a prospective research biopsy protocol for pts with known or suspected metastatic breast cancer. Pts were included in the present analysis if they received neoadjuvant chemotherapy (NAC) for stage I-III TNBC (eTNBC), or if they were diagnosed with any stage TNBC and ultimately developed metastatic TNBC (mTNBC). Clinical pathology records were reviewed for HER2 IHC results of samples collected at: initial diagnosis (DX); residual disease (RD) post-NAC, if applicable; and at recurrence (M). HER2 IHC was classified as HER2-0 if HER2 IHC 0, and HER2-low if 1+ or 2+ (and ISH non-amplified). For matched comparisons, if IHC was performed in more than one DX sample (e.g., breast, node), only the breast was considered; if more than one M sample, only the first M biopsy with available IHC was considered. Results: Among 110 pts in this cohort, 101 were initially diagnosed with eTNBC (79 received NAC; 22 underwent surgery as first intervention) and 9 with de novo mTNBC. Median age was 48.7 years (range 19.8-71.6). Among all pts, a total of 292 samples (136 DX, 53 RD, 103 M) had available HER2 IHC scores. When restricting to one sample per time point, HER2-low prevalence was 49/102 (48.0%) in DX breast tumors, 21/53 (39.6%) in RD, and 13/58 (22.4%) in first M samples (with all remaining samples HER2-0, except one HER2 3+ sample). In eTNBC pts, HER2 IHC scores were available for 50 paired DX and RD, and 48 paired DX and M samples. Among 50 pts with paired DX and RD, HER2 IHC was discordant in 56% (28/50) (Table 1). Of the 21 HER2-0 DX tumors, 23.8% (5/21) became HER2-low at RD. Of the 29 HER2-low DX tumors, 51.7% (15/29) became HER2-0 at RD. Among 48 eTNBC pts who recurred and had paired DX and M samples, HER2 IHC was discordant in 50% (24/48) (Table 1). Change from HER2-0 to low was 12.5% (3/24), and from HER2-low to HER2-0 was 66.7% (16/24). Among 9 de novo mTNBC pts, 5 had HER2 IHC available in paired DX breast and M prior to starting therapy; 3 were concordant (IHC 0, n=2; IHC 1+, n=1), one had IHC 0 in DX breast and IHC 2+ in M (liver), one had IHC 1+ in DX breast and IHC 0 in M (node). Conclusions: HER2 IHC classification was discordant in about half of the TNBC cases we examined, with more frequent rates of conversion from HER2-low to HER2-0 in both paired DX/RD post-NAC, and paired DX/M samples. Additional analyses will be presented exploring HER2 IHC changes among multiple metastases per patient. Genomic and molecular analysis, including whole exome sequencing, RNA sequencing, and methylation profiling, are underway in these samples to further elucidate HER2 evolutionary dynamics. Citation Format: Ana C. Garrido-Castro, Lan D. Ngo, Edward T. Richardson, Allison Frangieh, Ayesha Mohammed-Abreu, Melissa E. Hughes, Jorge Gomez Tejada Zanudo, John Navarro, Paolo Tarantino, Elizabeth A. Mittendorf, Sara Tolaney, Tari King, Eric Winer, Nancy U. Lin, Nikhil Wagle. HER2-10 Dynamics of HER2-low expression in triple-negative breast cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl) nr HER2-10.

oncology

A Hybrid Deep Architecture for Face Recognition in Real-Life Scenario

Clinical and biological heterogeneity in triple-negative breast cancer and HER2-low.

HER2-Low Status Was Associated With Better Breast Cancer-Specific Survival in Early-Stage Triple-Negative Breast Cancer

Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer

Clinicopathologic Characteristics of Triple-Negative Breast Cancer

[Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].

A Study on Pertinence of Pathologic and Biology Features in HER-2, ER and PR Negative Breast Cancer

Triple-negative Breast Cancer Types Exhibit a Distinct Poor Clinical Characteristic in Lymph Node-Negative Chinese Patients

Genomic Alterations of Tumors in HER2-Low Breast Cancers

Clinicopathologic and Genomic Features in Triple-Negative Breast Cancer Between Special and No-Special Morphologic Pattern

Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers

Molecular characteristics and prognosis of breast cancer patients with different level of HER2 positivity after adjuvant and neoadjuvant chemotherapy

Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer

Abstract P1-11-06: Multi-omics Profiling of HER2-low Breast Cancer Reveals Clinically Relevant Subgroups and Therapeutic Pathways

Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review

Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: A single-center retrospective study

Evolving Perspectives in Clinical Landscape and Molecular Characteristics of HER2-Low Breast Cancer and Beyond

In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China

Multiomics and single-cell sequencings reveal the specific biological characteristics of low Ki-67 triple-negative breast cancer

Abstract HER2-10: HER2-10 Dynamics of HER2-low expression in triple-negative breast cancer